No profile data available.
Evotec SE (EVO) is a healthcare company in the medication development research industry, based in Hamburg, Germany, with about 4,788 full-time employees.
It reported revenue of 788.37 million EUR for fiscal year 2025, down 1.1% from fiscal year 2024, and net income of -103.52 million EUR. In Q2 2026 (the quarter ended June 30, 2026) revenue was 143.48 million EUR, down 16.2% from a year before. Its market capitalization was $1.15 billion as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Evotec reported 788.37 million EUR in revenue for fiscal year 2025, down 1.1% from 796.97 million EUR in fiscal year 2024. In Q2 2026 revenue was 143.48 million EUR.
$1.15 billion as of December 4, 2025.
Listed companies of a similar size in the same industry (medication development research) include AbCellera Biologics Inc. (ABCL), Recursion Pharmaceuticals, Inc. (RXRX), Absci Corporation (ABSI), C4 Therapeutics, Inc. (CCCC).